Xencor's XmAb®5871 Program to be Featured in Poster Presentation at European...
(Source: Xencor Inc) MONROVIA, Calif., May 11, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...
MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...
MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...
(Source: Xencor Inc) MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor Reports Third Quarter 2014 Financial Results Conference call today at...
, Nov. 10, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...
View ArticleXencor Reports Third Quarter 2014 Financial Results (Xencor Inc)
(Source: Xencor Inc) Conference call today at 4:30 p.m. EST MONROVIA, Calif., Nov. 10, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered...
View ArticleXencor Reports First Quarter 2015 Financial and Operating Results
, May 4, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...
View ArticleXencor Reports First Quarter 2015 Financial and Operating Results (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., May 4, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing...
(Source: Xencor Inc) MONROVIA, Calif., May 18, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor's Partner Initiates Phase 2 Clinical Trial of a Biologic Candidate...
MONROVIA, Calif., Sept. 24, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor to Host Second Quarter 2016 Financial Results Webcast and Conference...
(Source: Xencor Inc) MONROVIA, Calif., July 26, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor to Host Fourth Quarter and Full Year 2016 Financial Results Webcast...
(Source: Xencor Inc) MONROVIA, Calif., Feb. 22, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor to Host Analyst Day and Webcast on June 28, 2016 (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., June 14, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor to Host Third Quarter 2016 Financial Results Webcast and Conference...
(Source: Xencor Inc) MONROVIA, Calif., Oct. 26, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor to Present at Upcoming Investor Conferences (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., Oct. 31, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor to Present at Leerink Partners 6th Annual Global Healthcare Conference...
(Source: Xencor Inc) MONROVIA, Calif., Feb. 9, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor to Present at Oppenheimer 27th Annual Healthcare Conference
MONROVIA, Calif., March 15, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleIgG4-Related Disease Biomarker Development Update Presented From an Ongoing,...
(Source: Xencor Inc) MONROVIA, Calif., Feb. 18, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleIgG4-Related Disease Biomarker Development Update Presented From an Ongoing,...
MONROVIA, Calif., Feb. 18, 2017 /PRNewswire/ -- Xencor, Inc. XNCR, +2.10% a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticlePreliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in...
(Source: Xencor Inc) MONROVIA, Calif., Oct. 3, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View Article